Gilotrif FDA Approval History
FDA Approved: Yes (First approved July 12, 2013)
Brand name: Gilotrif
Generic name: afatinib
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Non-Small Cell Lung Cancer
Gilotrif (afatinib) is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Development timeline for Gilotrif
| Date | Article |
|---|---|
| Jan 16, 2018 | Approval FDA Approves New Indication for Gilotrif (afatinib) in EGFR Mutation-Positive NSCLC |
| Apr 15, 2016 | Approval FDA Approves Gilotrif (afatinib) for Patients with Squamous Cell Carcinoma of the Lung |
| Jul 12, 2013 | Approval FDA Approves Gilotrif for Late Stage Non-Small Cell Lung Cancer |
| Jan 15, 2013 | U.S. FDA Grants Priority Review to Boehringer Ingelheim's Afatinib NDA for EGFR Mutation-Positive Advanced NSCLC |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
